Full-Time

Med Tech Supply Chain PMO Excellence Lead

Deadline 9/9/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$122k - $212.8k/yr

+ Long-term incentive program

New Brunswick, NJ, USA + 2 more

More locations: Raritan, NJ, USA | Jacksonville, FL, USA

Hybrid

Up to 25% international and domestic travel required.

Bachelor's

Category
Project & Program Management (1)
Required Skills
Power BI
Supply Chain Management
Data Visualization
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A bachelor's degree in engineering, supply chain, or an equivalent field is required.
  • Project Management Certification is required.
  • A minimum of 10 years of combined hands-on experience in Operations, Supply Chain, Engineering, or an equivalent area is required.
  • A minimum of 5 years of large-scale program and project management experience in a matrixed organization, including experience managing projects of varied types and complexity, is required.
  • A minimum of 3 years of experience with operational excellence and continuous improvement is required.
  • Knowledge and ability to lead global portfolios, programs, and enterprise transformations in complex, cross-functional stakeholder environments.
  • Experience designing and implementing program governance structures, including risk frameworks, escalation protocols, and executive reporting mechanisms.
  • Strong business acumen, including industry and domain-specific knowledge of the end-to-end supply chain and its business units.
  • Leadership ability to develop and communicate the PMO vision and motivate the project management community and staff.
  • Ability to influence without authority, align diverse stakeholders, manage ambiguity, and drive adoption of new capabilities across functions and geographies.
  • Experience supporting organizational change, project and program management capability building, training, and continuous improvement in complex matrix environments.
  • Strong executive communication and storytelling skills, including simplifying complex information and creating clear recommendations for senior leaders and cross-functional forums.
  • Analytical, strategic conceptual thinking, strategic planning, and execution skills.
  • Ability to align investments, resources, and initiatives with strategic business objectives.
  • Ability to develop and execute a strategic resource plan.
  • Deep understanding of current and emerging technologies related to project management.
  • Significant knowledge of project planning tools, with practical application on complex and varied programs.
  • Experience partnering with Digital and Data teams to deliver scalable reporting, dashboarding, visualization, analytics, and business intelligence solutions.
  • Experience leading organizational change management efforts, including process redesign, tooling transitions, or operating model transformations at global scale.
Responsibilities
  • Facilitate consensus among PMO stakeholders and organizational leadership around the mission and vision of the PMO organization.
  • Engage senior leadership and business partners to define the PMO mission, goals, and operating model in the PMO charter.
  • Lead the identification and development of PMO roles, team configuration, and recruitment needed to deliver agreed-upon PMO goals and objectives.
  • Lead the identification and implementation of project management processes, methods, tools, guidelines, and standards to improve initiative delivery.
  • Facilitate portfolio planning and prioritization processes to prioritize investments, balance resource capacity, and align initiative execution with strategic business priorities.
  • Define, manage, and direct the end-to-end PMO work effort, including identifying, quantifying, and tracking the realization of expected benefits defined in business cases.
  • Provide ongoing coaching and mentoring to PMO staff.
  • Build and maintain relationships with senior leadership and key PMO stakeholders and act as a trusted advisor.
  • Regularly review and evaluate opportunities to improve project, program, and portfolio management best practices.
  • Lead the establishment of a project management community of practice when agreed and needed to facilitate collaboration and best-practice sharing among practitioners.
  • Assess enterprise or portfolio performance using metrics and reporting to support progression toward a value-based operating model.
  • Assure strategic alignment through prioritization, resource capacity management, key result tracking, and project and program management.
  • Execute programs and enterprise transformations in complex, cross-functional stakeholder environments.
Desired Qualifications
  • Experience with artificial intelligence.
  • Experience with Power BI.
  • Experience with Quickbase.
  • Experience with Planisware.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.